Ozempic, Wegovy, Mounjaro
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky
Life-changing medicine or beauty hack? How Ozempic came to be seen as both, and why that's risky The same drug that is helping patients manage diabetes and reduce their risk of serious complications from chronic conditions is also being discussed as a beauty hack by people hoping to lose a few kilograms. Experts say more education and awareness are needed.
Weight-loss jabs could slash cancer risk 41 per cent, experts say
Weight-loss jabs could slash cancer risk 41 per cent, experts say A major new study looks at thousands of people taking the medication Weight loss jabs could should be investigated as potential “cancer prevention agents”, experts have said after a study linked the medication to a reduced risk of cancers linked to obesity. Being overweight or obese has been linked to an increased risk of 13 types of cancer including of the breast, bowel, pancreas, kidney, liver and stomach. Glucagon-like...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The...
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It may be fewer injections. Pfizer and Amgen are developing monthly GLP-1 shots — a departure from injections like Wegovy and Zepbound, which are taken weekly.